Eris Biotech
Our drugs engage the immune system to fight tumors
Monthly revenue–Not shared yet
Rank–Unranked
Last 30 days–Growth in MRR
Revenue per founder–– founders
About Eris Biotech
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
Discover more startups
Browse the board →MRR
$251K
Last 30 days
-2%
Founder
Jacob Jacquet
MRR
$250K
Last 30 days
0%
Founder
Eugene Zolotarenko
MRR
$250K
Last 30 days
0%
Founder
Valon Asani